cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.krax5r
title: Occurrence Download

description: A dataset containing 800 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Rubus leucostachys",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present"
 ]
}

 The dataset includes 800 records from 28 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012632-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.hh9x3c
title: Occurrence Download

description: A dataset containing 29683 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Rostratula benghalensis",
 "Geometry POLYGON((119.300000 20.500000, 122.100000 20.500000, 122.100000 25.400000, 119.300000 25.400000, 119.300000 20.500000))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false"
 ]
}

 The dataset includes 29683 records from 21 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012631-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.c94h84
title: Occurrence Download

description: A dataset containing 31885 species occurrences available in GBIF matching the query:
{
 "and" : [
 {
 "and" : [
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is one of (Fossil, Living Specimen)"
 ]
 }
 }
 ]
 },
 "TaxonKey is one of (Aster amellus)"
 ]
}

 The dataset includes 31885 records from 348 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012633-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.rggfpq
title: Occurrence Download

description: A dataset containing 747 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is one of (Machine Observation, Human Observation)",
 "Country is New Zealand",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "TaxonKey is Apteryx rowi"
 ]
}

 The dataset includes 747 records from 6 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012634-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.17194849
title: Restraint of cancer cell plasticity by spatial homotypic clustering

description: Data for manuscript Migliozzi et. al "Restraint of cancer cell plasticity by spatial homotypic clustering" Cancer Cell.
DOI: 10.15468/dl.vp88eu
title: Occurrence Download

description: A dataset containing 60 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Brycon gouldingi"
 ]
}

 The dataset includes 60 records from 10 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012635-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.bzvddx
title: Occurrence Download

description: A dataset containing 4451 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Rubus macrophyllus",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present"
 ]
}

 The dataset includes 4451 records from 113 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012636-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.6k2vx9
title: Occurrence Download

description: A dataset containing 178 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Callistemon rigidus",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present"
 ]
}

 The dataset includes 178 records from 57 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012637-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.e99t5g
title: Occurrence Download

description: A dataset containing 18 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Clinopodium nepeta",
 "Country is Czechia",
 "HasCoordinate is true"
 ]
}

 The dataset includes 18 records from 4 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012639-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.twun5k
title: Occurrence Download

description: A dataset containing 158 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Clinopodium nepeta",
 "Country is Belgium",
 "HasCoordinate is true"
 ]
}

 The dataset includes 158 records from 8 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012638-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.8bmb9z
title: Occurrence Download

description: A dataset containing 237 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Clinopodium nepeta",
 "Country is United States of America",
 "HasCoordinate is true"
 ]
}

 The dataset includes 237 records from 30 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012641-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.jbyad6
title: Occurrence Download

description: A dataset containing 37 species occurrences available in GBIF matching the query:
{
 "and" : [
 {
 "and" : [
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is one of (Fossil, Living Specimen)"
 ]
 }
 }
 ]
 },
 "TaxonKey is one of (Aster azureus)"
 ]
}

 The dataset includes 37 records from 15 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012642-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.5fsmmn
title: Occurrence Download

description: A dataset containing 3287 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Herpetofauna, avifauna y plantas de Puerto Salgar, Caparrapí, Guaduas y Quebradanegra (Cundinamarca)"
 ]
}

 The dataset includes 3287 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012643-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.c93775
title: Occurrence Download

description: A dataset containing 1252 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Censos de aves en los municipios de Honda (Tolima) y Guaduas (Cundinamarca) - BIO Alas, cantos y colores"
 ]
}

 The dataset includes 1252 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012644-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.17194839
title: Test dataset for pyudon: Cohort of 21 SJIA patients and 5 controls

description: Example h5ad for pyudon's tutorial. Contains raw counts of PBMC scRNA-seq datasets from 21 pediatric patients with SJIA and 5 controls. The raw individual h5 files of each sample can be found on GEO at GSE207633.
DOI: 10.15468/dl.5nn3sk
title: Occurrence Download

description: A dataset containing 656 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Expedición ornitológica en los municipios de Honda, Fresno (Tolima) y Guaduas (Cundinamarca) - BIO Alas, cantos y colores"
 ]
}

 The dataset includes 656 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012645-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.x9syb2
title: Occurrence Download

description: A dataset containing 6559 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Rubus moluccanus",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present"
 ]
}

 The dataset includes 6559 records from 65 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012647-250920141307145/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.26195999
title: Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review

description: Due to its anti-angiogenic properties, trebananib is frequently employed in the treatment of cancer patients, particularly those with ovarian cancer. We conducted a meta-analysis to assess the efficacy and safety profile of trebananib in combination with other drugs for treating both ovarian and non-ovarian cancer patients. Our search encompassed PubMed, Medline, Cochrane, and Embase databases, with a focus on evaluating study quality. Data extraction was conducted from randomized controlled trials (RCTs), and RevMan 5.3 facilitated result analysis. Combining trebananib with other drugs extended progression-free survival (PFS) [HR 0.81, (95%CI: 0.65, 0.99), <i>p</i> = 0.04] and overall survival (OS) [HR 0.88, (95%CI: 0.79, 1.00), <i>p</i> = 0.04] in ovarian cancer patients. Ovarian cancer patients exhibited a higher objective response rate (ORR) with trebananib compared to non-ovarian cancer cohorts. Moreover, the incorporation of trebananib into the standard treatment regimen for malignant tumors did not significantly elevate drug-related adverse events [RR 1.05, (95% CI: 1.00, 1.11), <i>p</i> = 0.05]. Trebananib plus other drugs can improve the PFS, OS and ORR in patients with cancer, especially ovarian cancer. Our recommendation is to use trebananib plus other drugs to treat advanced cancer, and to continuously monitor and manage drug-related adverse events. PROSPERO (No. CRD42023466988)
DOI: 10.6084/m9.figshare.26195999.v1
title: Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review

description: Due to its anti-angiogenic properties, trebananib is frequently employed in the treatment of cancer patients, particularly those with ovarian cancer. We conducted a meta-analysis to assess the efficacy and safety profile of trebananib in combination with other drugs for treating both ovarian and non-ovarian cancer patients. Our search encompassed PubMed, Medline, Cochrane, and Embase databases, with a focus on evaluating study quality. Data extraction was conducted from randomized controlled trials (RCTs), and RevMan 5.3 facilitated result analysis. Combining trebananib with other drugs extended progression-free survival (PFS) [HR 0.81, (95%CI: 0.65, 0.99), <i>p</i> = 0.04] and overall survival (OS) [HR 0.88, (95%CI: 0.79, 1.00), <i>p</i> = 0.04] in ovarian cancer patients. Ovarian cancer patients exhibited a higher objective response rate (ORR) with trebananib compared to non-ovarian cancer cohorts. Moreover, the incorporation of trebananib into the standard treatment regimen for malignant tumors did not significantly elevate drug-related adverse events [RR 1.05, (95% CI: 1.00, 1.11), <i>p</i> = 0.05]. Trebananib plus other drugs can improve the PFS, OS and ORR in patients with cancer, especially ovarian cancer. Our recommendation is to use trebananib plus other drugs to treat advanced cancer, and to continuously monitor and manage drug-related adverse events. PROSPERO (No. CRD42023466988)
DOI: 10.6084/m9.figshare.26206392
title: Screening of genes related to programmed cell death in esophageal squamous cell carcinoma and construction of prognostic model based on transcriptome analysis

description: To screen programmed cell death (PCD)-related genes in esophageal squamous cell carcinoma (ESCC) based on transcriptomic data and to explore its clinical value. Differentially expressed PCD genes (DEPCDGs) were screened from ESCC transcriptome and clinical data in TCGA database. Univariate COX and LASSO COX were performed on prognostically DEPCDGs in ESCC to develop prognostic model. Differences in immune cell infiltration in different RiskScore groups were determined by ssGSEA and CIBERSORT. The role of RiskScore in immunotherapy response was explored using Tumor Immune Dysfunction and Exclusion (TIDE) and IMvigor210 cohorts. Fourteen DEPCDGs associated with prognosis were tapped in ESCC. These DEPCDGs form a RiskScore with good predictive performance for prognosis. RiskScore demonstrated excellent prediction accuracy in three data sets. The abundance of M2 macrophages and Tregs was higher in the high RiskScore group, and the abundance of M1 macrophages was higher in the low RiskScore group. The RiskScore also showed good immunotherapy sensitivity. RT-qPCR analysis showed that AUP1, BCAP31, DYRK2, TAF9 and UBQLN2 were higher expression in KYSE-150 cells. Knockdown BCAP31 inhibited migration and invasion. A prognostic risk model can predict prognosis of ESCC and may be a useful biomarker for risk stratification and immunotherapy assessment.
DOI: 10.6084/m9.figshare.26206392.v1
title: Screening of genes related to programmed cell death in esophageal squamous cell carcinoma and construction of prognostic model based on transcriptome analysis

description: To screen programmed cell death (PCD)-related genes in esophageal squamous cell carcinoma (ESCC) based on transcriptomic data and to explore its clinical value. Differentially expressed PCD genes (DEPCDGs) were screened from ESCC transcriptome and clinical data in TCGA database. Univariate COX and LASSO COX were performed on prognostically DEPCDGs in ESCC to develop prognostic model. Differences in immune cell infiltration in different RiskScore groups were determined by ssGSEA and CIBERSORT. The role of RiskScore in immunotherapy response was explored using Tumor Immune Dysfunction and Exclusion (TIDE) and IMvigor210 cohorts. Fourteen DEPCDGs associated with prognosis were tapped in ESCC. These DEPCDGs form a RiskScore with good predictive performance for prognosis. RiskScore demonstrated excellent prediction accuracy in three data sets. The abundance of M2 macrophages and Tregs was higher in the high RiskScore group, and the abundance of M1 macrophages was higher in the low RiskScore group. The RiskScore also showed good immunotherapy sensitivity. RT-qPCR analysis showed that AUP1, BCAP31, DYRK2, TAF9 and UBQLN2 were higher expression in KYSE-150 cells. Knockdown BCAP31 inhibited migration and invasion. A prognostic risk model can predict prognosis of ESCC and may be a useful biomarker for risk stratification and immunotherapy assessment.
DOI: 10.6084/m9.figshare.26310227
title: A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020–present

description: Cyclin-dependent protein kinase 4/6 (CDK4/6) is a class of serine/threonine protein kinases that plays a key role in the regulation of the cell cycle. CDK4/6 is highly expressed in cancers such as breast cancer, melanoma, and non-small cell lung cancer (NSCLC). Currently, a variety of CDK4/6 inhibitors have been developed, aiming to develop effective inhibitors to solve CDK4/6 resistance and toxicity. This article searches patents through Espacenet and reviews the development of widely studied CDK inhibitors and FDA-approved CDK4/6 inhibitors, as well as the latest progress of patented inhibitors with good inhibitory activity against CDK4/6 from 2020 to now. CDK4/6 is highly expressed in many tumors and has become an important anti-tumor target. Among the patents from 2020 to the present, many inhibitors have good kinase inhibitory effects on CDK4/6 and also show great development potential in anti-tumor. However, there is still an urgent need to develop novel CDK4/6 inhibitors that address challenges such as drug resistance, toxicity, and selectivity.
DOI: 10.6084/m9.figshare.26310227.v2
title: A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020–present

description: Cyclin-dependent protein kinase 4/6 (CDK4/6) is a class of serine/threonine protein kinases that plays a key role in the regulation of the cell cycle. CDK4/6 is highly expressed in cancers such as breast cancer, melanoma, and non-small cell lung cancer (NSCLC). Currently, a variety of CDK4/6 inhibitors have been developed, aiming to develop effective inhibitors to solve CDK4/6 resistance and toxicity. This article searches patents through Espacenet and reviews the development of widely studied CDK inhibitors and FDA-approved CDK4/6 inhibitors, as well as the latest progress of patented inhibitors with good inhibitory activity against CDK4/6 from 2020 to now. CDK4/6 is highly expressed in many tumors and has become an important anti-tumor target. Among the patents from 2020 to the present, many inhibitors have good kinase inhibitory effects on CDK4/6 and also show great development potential in anti-tumor. However, there is still an urgent need to develop novel CDK4/6 inhibitors that address challenges such as drug resistance, toxicity, and selectivity.
DOI: 10.6084/m9.figshare.26310227.v1
title: A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020—present

description: Cyclin-dependent protein kinase 4/6 (CDK4/6) is a class of serine/threonine protein kinases that plays a key role in the regulation of the cell cycle. CDK4/6 is highly expressed in cancers such as breast cancer, melanoma, and non-small cell lung cancer (NSCLC). Currently, a variety of CDK4/6 inhibitors have been developed, aiming to develop effective inhibitors to solve CDK4/6 resistance and toxicity. This article searches patents through Espacenet and reviews the development of widely studied CDK inhibitors and FDA-approved CDK4/6 inhibitors, as well as the latest progress of patented inhibitors with good inhibitory activity against CDK4/6 from 2020 to now. CDK4/6 is highly expressed in many tumors and has become an important anti-tumor target. Among the patents from 2020 to the present, many inhibitors have good kinase inhibitory effects on CDK4/6 and also show great development potential in anti-tumor. However, there is still an urgent need to develop novel CDK4/6 inhibitors that address challenges such as drug resistance, toxicity, and selectivity.
DOI: 10.15468/dl.d2ajm8
title: Occurrence Download

description: A dataset containing 53 species occurrences available in GBIF matching the query:
{
 "Geometry" : [
 "POLYGON ((147.664321 -35.812043, 147.664321 -35.825518, 147.662075 -35.825518, 147.662075 -35.823272, 147.653092 -35.823272, 147.653092 -35.825518, 147.646355 -35.825518, 147.646355 -35.827763, 147.655338 -35.827763, 147.655338 -35.843484, 147.671058 -35.843484, 147.671058 -35.852467, 147.680041 -35.852467, 147.680041 -35.872679, 147.684533 -35.872679, 147.684533 -35.877171, 147.698008 -35.877171, 147.698008 -35.872679, 147.700254 -35.872679, 147.700254 -35.870434, 147.686779 -35.870434, 147.686779 -35.865942, 147.69127 -35.865942, 147.69127 -35.863696, 147.693516 -35.863696, 147.693516 -35.86145, 147.69127 -35.86145, 147.69127 -35.854713, 147.698008 -35.854713, 147.698008 -35.838992, 147.69127 -35.838992, 147.69127 -35.832255, 147.677796 -35.832255, 147.677796 -35.827763, 147.67555 -35.827763, 147.67555 -35.825518, 147.671058 -35.825518, 147.671058 -35.823272, 147.668812 -35.823272, 147.668812 -35.81878, 147.671058 -35.81878, 147.671058 -35.812043, 147.664321 -35.812043), (147.671058 -35.843484, 147.671058 -35.841238, 147.668812 -35.841238, 147.668812 -35.838992, 147.67555 -35.838992, 147.67555 -35.843484, 147.671058 -35.843484), (147.686779 -35.847976, 147.69127 -35.847976, 147.69127 -35.850221, 147.686779 -35.850221, 147.686779 -35.847976), (147.680041 -35.838992, 147.686779 -35.838992, 147.686779 -35.843484, 147.684533 -35.843484, 147.684533 -35.841238, 147.680041 -35.841238, 147.680041 -35.838992), (147.662075 -35.827763, 147.664321 -35.827763, 147.664321 -35.832255, 147.662075 -35.832255, 147.662075 -35.827763))"
 ]
}

 The dataset includes 53 records from 7 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0053847-240626123714530/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.1594/pangaea.961087
title: Surface layer permittivity at 50 MHz measured during RV POLARSTERN cruise PS131

description: This dataset contains measurements of dielectric permittivity and dielectric loss of the surface layer by impedance measurements at 50 MHz on several ice stations during the Polarstern cruise PS131 in the marginal ice zone in the Fram Strait between mid-July and 6th of August 2022. Measurements were performed using the Stevens Water Monitoring Systems Hydra Probe Sensor. Samples were mainly obtained by vertically inserting the probe tines of the device into the surface scattering layer on top of the sea ice and collecting data in one-minute intervals for several minutes. The cylindrical measurement region of the sensor has a length of 5.7 cm and a diameter of 3 cm, i.e., the upper 5.7 cm of the surface are measured. In the few cases of horizontal placement, the upper 3 cm are thus measured (if not indicated otherwise in the column Comment of the dataset). The dataset contains both mean and standard deviation of each placement. The dataset also contains temperature (measured in the center between surface and visually determined interface of surface layer and ice), salinity (by taking samples of the upper few cm of the surface layer) and density measurements (of the upper 3 cm of the surface layer), all independent of the Hydra Probe device. For more information of these measurements the user is referred to Chapter 8 of the cruise report. The columns "Site" and "Floe" refer to the nomenclature used in that cruise report with the sites being relative positions on the floes as shown in Figure 3.2.3 therein.
DOI: 10.1594/pangaea.961656
title: Sea ice temperature profiles measured during RV POLARSTERN cruise PS131

description: Ice core samples were obtained with a 9 cm Kovacs corer during the Polarstern cruise PS131 on ice stations between mid-July and 6th of August 2022 in the marginal ice zone in the Fram Strait and at two ice stations on fast ice (Greenland). This dataset contains temperature profiles obtained by drilling holes in 4 cm intervals (for the upper 40cm) and 10 cm intervals for the rest and inserting a waterproof thermometer with a needle probe. For most of the samples, the whole ice layer was sampled, but for some, only the upper 40 cm were measured. However, the measured total ice thickness is included in the dataset. For more information of these measurements the user is referred to Chapter 8 of the cruise report.